Biomea Fusion Signs Collaboration with University of Leicester to Evaluate Icovamenib-Semaglutide Combination in Obesity

A clinical question with direct CMC and supply-chain consequences is now entering a structured trial framework: Biomea Fusion has activated an experimental arm within the University of Leicester's OPAL platform study to evaluate its investigational menin inhibitor, icovamenib, in combination with semaglutide in overweight and obese adults without type 2 diabetes. For development teams tracking next-generation obesity combinations, the study design and enrollment timeline carry immediate planning implications.

The newly activated arm will administer icovamenib at 100 mg once daily for 12 weeks alongside low-dose semaglutide for 24 weeks, compared against low-dose semaglutide alone. The randomized, double-blind study will begin enrollment in Q3 2026, with the primary outcome assessment at Week 24. Endpoints span body weight, body composition, physical function, muscle health, and metabolic outcomes, a broader efficacy profile than weight reduction alone.

The collaboration sits within OPAL (Investigating and Optimizing Physical Function with Weight Loss), a multi-arm open-label adaptive platform trial led by Professors Melanie Davies and Thomas Yates at the Leicester Diabetes Centre. Adaptive platform designs of this type allow multiple experimental arms to run concurrently against a shared comparator, compressing development timelines but demanding tighter investigational medicinal product (IMP) supply coordination across arms.

Preclinical data cited by Biomea showed synergistic effects between icovamenib and semaglutide, including enhanced weight loss and signals on bone and muscle biology. Those findings are being presented as late-breaking data at the American Diabetes Association Annual Meeting, June 5–8, 2026. The clinical study is designed to test whether those preclinical signals translate, with particular focus on lean mass preservation, an area of increasing regulatory and clinical scrutiny as GLP-1 class therapies scale.

For formulation and CMC teams, the combination introduces a dual-agent IMP supply requirement: a small-molecule menin inhibitor alongside a peptide-based GLP-1 receptor agonist. Stability profiling, packaging configuration, and blinding logistics for a 24-week randomized trial will require early engagement with clinical supply functions, particularly given the Q3 enrollment start.

The Week 24 primary outcome readout will be a measurable checkpoint for whether icovamenib's preclinical muscle and bone signals hold in a clinical population, and will inform whether broader Phase 2 combination development is warranted.

Source: Biomea Fusion, Inc. via GlobeNewswire, June 3, 2026. Late-breaking preclinical data presented at the American Diabetes Association Annual Meeting, June 5–8, 2026.